Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial.


Journal

Addictive behaviors
ISSN: 1873-6327
Titre abrégé: Addict Behav
Pays: England
ID NLM: 7603486

Informations de publication

Date de publication:
04 2019
Historique:
received: 18 04 2018
revised: 01 10 2018
accepted: 28 10 2018
pubmed: 6 11 2018
medline: 17 6 2020
entrez: 6 11 2018
Statut: ppublish

Résumé

There is limited evidence about the effects of dual electronic cigarette (e-cig) and combustible cigarette use on lung health or other health outcomes. Studies that have evaluated these outcomes have not included estimates of e-cig or cigarette exposure in the analyses. Data analyzed were from 263 smokers participating in a randomized controlled trial designed to encourage participants to reduce their combustible cigarette use by substituting with an e-cig or a non-electronic cigarette substitute (cig-sub). t-tests were used to evaluate changes from baseline at 1 month and 3 months in lung function, blood pressure, pulse, exhaled carbon monoxide, and weight. Linear mixed effects models were used to test associations between health outcomes and study product group, including exposure to the study products (e-cig and cig-sub times used and days used in the past 7 days) and cigarettes per day (CPD). There were few significant differences between the groups for lung function indices at any time point in the unadjusted analyses. There were significant reductions in diastolic blood pressure and pulse at 1 month in the unadjusted analyses for those in the e-cig group compared to the cig-sub group. CPD decreased significantly more for the e-cig group than for the cig-sub group at both time points. There were no significant associations between any measured health outcomes and group in the linear mixed effects models. E-cig use did not contribute to significant changes in health outcome markers as compared with use of a non-electronic cig-sub.

Sections du résumé

BACKGROUND
There is limited evidence about the effects of dual electronic cigarette (e-cig) and combustible cigarette use on lung health or other health outcomes. Studies that have evaluated these outcomes have not included estimates of e-cig or cigarette exposure in the analyses.
MATERIALS AND METHODS
Data analyzed were from 263 smokers participating in a randomized controlled trial designed to encourage participants to reduce their combustible cigarette use by substituting with an e-cig or a non-electronic cigarette substitute (cig-sub). t-tests were used to evaluate changes from baseline at 1 month and 3 months in lung function, blood pressure, pulse, exhaled carbon monoxide, and weight. Linear mixed effects models were used to test associations between health outcomes and study product group, including exposure to the study products (e-cig and cig-sub times used and days used in the past 7 days) and cigarettes per day (CPD).
RESULTS
There were few significant differences between the groups for lung function indices at any time point in the unadjusted analyses. There were significant reductions in diastolic blood pressure and pulse at 1 month in the unadjusted analyses for those in the e-cig group compared to the cig-sub group. CPD decreased significantly more for the e-cig group than for the cig-sub group at both time points. There were no significant associations between any measured health outcomes and group in the linear mixed effects models.
CONCLUSION
E-cig use did not contribute to significant changes in health outcome markers as compared with use of a non-electronic cig-sub.

Identifiants

pubmed: 30393015
pii: S0306-4603(18)31250-4
doi: 10.1016/j.addbeh.2018.10.041
pmc: PMC6358505
mid: NIHMS1511741
pii:
doi:

Substances chimiques

Carbon Monoxide 7U1EE4V452

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

95-101

Subventions

Organisme : NIDA NIH HHS
ID : P50 DA036105
Pays : United States
Organisme : NIDA NIH HHS
ID : U54 DA036105
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000058
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Eur Addict Res. 2014;20(5):218-25
pubmed: 24714502
Inhal Toxicol. 2013 Feb;25(2):91-101
pubmed: 23363041
Am J Respir Crit Care Med. 2018 Jul 1;198(1):123-126
pubmed: 29451806
Circulation. 2014 Oct 14;130(16):1418-36
pubmed: 25156991
Cancer Prev Res (Phila). 2015 Sep;8(9):873-8
pubmed: 26333731
Clin Sci (Lond). 2016 Nov 1;130(21):1929-37
pubmed: 27543458
Am J Respir Crit Care Med. 2018 Feb 15;197(4):492-501
pubmed: 29053025
Intern Emerg Med. 2016 Feb;11(1):85-94
pubmed: 26749533
BMC Public Health. 2016 Mar 03;16:217
pubmed: 26941050
Pediatrics. 2018 Jun;141(6):
pubmed: 29773665
Nicotine Tob Res. 2015 Feb;17(2):186-92
pubmed: 25332459
Addiction. 2011 Nov;106(11):2029-30
pubmed: 21978314
Regul Toxicol Pharmacol. 2016 Nov 15;81 Suppl 1:S1-S14
pubmed: 27769828
Thorax. 1997 Sep;52(9):820-7
pubmed: 9371217
Tob Control. 2009 Aug;18(4):324-32
pubmed: 19240228
Circulation. 2014 May 13;129(19):1972-86
pubmed: 24821826
Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 2):S257-65
pubmed: 8970398
Respir Care. 2006 Mar;51(3):246-51
pubmed: 16533413
Fed Regist. 2016 May 10;81(90):28973-9106
pubmed: 27192730
JAMA. 2014 Jan 8;311(2):135-6
pubmed: 24399548
Int J Environ Res Public Health. 2014 May 08;11(5):4965-77
pubmed: 24814944
Addiction. 2014 Nov;109(11):1801-10
pubmed: 25078252
Am J Respir Crit Care Med. 2018 Jul 1;198(1):67-76
pubmed: 29481290
Intern Emerg Med. 2014 Aug;9(5):537-46
pubmed: 23873169

Auteurs

Susan Veldheer (S)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States. Electronic address: sveldheer@psu.edu.

Jessica Yingst (J)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Vishal Midya (V)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Breianna Hummer (B)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Courtney Lester (C)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Nicolle Krebs (N)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Shari Hrabovsky (S)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Ashley Wilhelm (A)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Jason Liao (J)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Miao-Shan Yen (MS)

Virginia Commonwealth University, Center for the Study of Tobacco Products, 1112 East Clay St., Richmond, VA 23298, United States.

Caroline Cobb (C)

Virginia Commonwealth University, Center for the Study of Tobacco Products, 1112 East Clay St., Richmond, VA 23298, United States.

Thomas Eissenberg (T)

Virginia Commonwealth University, Center for the Study of Tobacco Products, 1112 East Clay St., Richmond, VA 23298, United States.

Jonathan Foulds (J)

Penn State University, Department of Public Health Sciences, Tobacco Center of Regulatory Science, College of Medicine, 500 University Dr., Hershey, PA 17033, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH